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Bacterial host interactions in cystic fibrosis
Ma´ire Callaghan and Siobha´n McClean
Chronic infection is a hallmark of cystic fibrosis (CF) and the
main contributor to morbidity. Microbial infection in CF is
complex, due to the number of different species that colonise
the CF lung. Their colonisation is facilitated by a host response
that is impaired or compromised by highly viscous mucous,
zones of hypoxia and the lack of the cystic fibrosis
transmembrane regulator (CFTR). Successful dominant CF
pathogens combine an effective arsenal to establish infection
and counter-attack the host response, together with an ability
to adapt readily to an unfavourable environment.
Hypermutability is common among CF pathogens facilitating
adaptation and as the host response persists, progressive
destruction of the normal architecture of lung tissue ensues
with catastrophic consequences for the host.
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Introduction
Cystic fibrosis is caused by mutations in the CFTR gene
leading to a disrupted chloride channel. It is well estab-
lished that the greatest contributor to patient morbidity
and mortality is chronic lung disease, caused by a constant
cycle of infection and inflammation throughout the
patient’s life (Figure 1). The CFTR mutation leads to
defective regulation of chloride and sodium, resulting in
increased water absorption, depletion of airway surface
liquid (ASL) and dehydrated mucous [1]. Consequently,
the purulent sputum and mucus plugs together with an
ineffective inflammatory response, all contribute to the
chronic infections that are central to CF lung disease.
From early childhood, CF patients experience recurrent
pulmonary infections from a range of pathogens. In spite
of intensive antibiotic therapy, certain organisms persist,
leading to pulmonary exacerbations, hospitalizations and
patient death (Box 1). These include Pseudomonas aer-
uginosa, Burkholderia cepacia complex (Bcc) and Achro-
mobacter xylosoxidans [2], with Bcc being the most
problematic. It was recently demonstrated  that chronic
colonisation by Bcc resulted in a greater lung function
decline than by the other two pathogens [3]. CF patients
are also susceptible to colonisation by other pathogens,
including Staphylococcus aureus (both Methicillin-resist-
ant and sensitive), genus Pandoraea, Stenotrophomonas
maltophilia and non-tuberculous Mycobacteria (NTM)
[4–6] although the role of these latter four pathogens
in CF lung disease is unclear. For example, a recent
paper investigating 21 patients colonised with S. mal-
tophilia without any other Gram negative organism,
showed that there was a comparable decline in lung
function in the two years after colonisation, to the three
years before its identification [6]. Furthermore, the
identification of high levels of anaerobic organisms in
CF sputum [7] has added to the complex microbial
population in the CF lung. These CF-associated anae-
robes were not susceptible to antibiotics with known
efficacy against anaerobes and the clinical significance
of anaerobes in CF is not yet fully understood [8].
Limited information exists on the host–microbial inter-
actions of many of these organisms and this review will
focus only on the current understanding of the more
clearly defined CF pathogens (Box 1).
Role of CFTR in CF lung colonisation
A direct role of the CFTR mutation in CF pathogenesis
has been attributed to normal CFTR acting as a pathogen
receptor involved in the internalisation and subsequent
clearance of P. aeruginosa [9], but this mechanism is
pathogen-specific. Mutated CFTR has also been attrib-
uted to be the cause of reduced internalisation of one Bcc
species, Burkholderia dolosa, but not the more virulent
Burkholderia cenocepacia in respiratory epithelial cells [10].
Furthermore, in contrast to P. aeruginosa, S. aureus was
more invasive of CF cells compared to non-CF cells [11],
indicating that CFTR is not the only route of bacterial
uptake and invasion into the epithelium.
Alterations in the phenotype of CF airway epithelial cells
also provide receptors for pathogens to adhere to. For
example, CF airways show alterations in membrane gly-
coproteins and glycolipids which are directly linked to the
CFTR defect (reviewed by [12]). The ratio of asialylated
to sialylated glycolipids is higher in CF cells compared to
non-CF cells, providing additional receptors for P. aeru-
ginosa and Bcc. This is significant as invasion of lung
epithelial cells by Bcc depends on asialylated glycolipids
[13]. In addition, alterations in specific fucosyl residues of
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membrane glycopeptides of CF cells provide receptors
for a fucose-specific P. aeruginosa lectin that is involved in
P. aeruginosa pathogenicity [14]. Furthermore, increased
glycosaminoglycan levels have been observed in CF air-
ways as recently reviewed by Reeves et al. [15] and may
contribute to CF lung disease. For example, increased
heparan sulphate prolongs the efficacy of cytokines, such
as interleukin (IL)-8, and also acts as a receptor for P.
aeruginosa. Finally, it has recently been shown that CFTR
deficiency in mice led to a reduction in acid sphingomye-
linase activity, allowing ceramide accumulation in lung
tissue [16]. The elevated ceramide resulted in increased
cell death and subsequent deposition of DNA in the
respiratory tracts, providing sites for P. aeruginosa attach-
ment [16]. This accumulation of ceramide was also
observed in CF patients and the treatment of a CF patient
with the acid sphingomyelinase inhibitor, amitriptyline
resulted in a greater than 10% improvement in lung
function [17].
The host immune response in the CF lung
The airway epithelium recognizes and responds to patho-
gens through the interaction between host pathogen
recognition receptors and pathogen-associated membrane
proteins. Toll like receptors (TLRs) such as TLR-4 on
epithelial surfaces interact with lipopolysaccharide result-
ing in the activation of cytokine and anti-microbial pep-
tide genes. TLR-2 signaling by P. aeruginosa has been
shown to initiate cleavage of intracellular junctional
72 Host-microbe interactions: bacteria
Figure 1
CF lung architecture
Compromised host
response
CF pathogens:
P. aeruginosa, Bcc,  MRSA,
A. xylosoxidans , NTM
Inflammation
Bacterial adaptation:
Antibiotic resistance
Iron acquisition,
Low O2 requirements
QS, loss of virulence factors
Mucoid/ non-mucoid
Other co-colonising
pathogens: e.g. S.
maltophilia,
anaerobic bacteria
Chronic Colonisation
Current Opinion in Microbiology
The cycle of infection and inflammation combined with bacterial adaptation allows bacteria to chronically colonise the CF host.
Box 1 Examples of bacteria isolated from CF lung and their
contribution to CF lung disease
Definite pathogen in CF
P. aeruginosa
Burkholderia cepacia complex (particularly B. cenocepacia)
Methicillin resistant Staphylococcus aureus
Likely pathogen in CF
Achromobacter xyloxidans
Non-tuberculous Mycobacteria
Unclear role in CF lung disease
Genus Pandoraea
Methicillin sensitive Staphylococcus aureus
Inquilinus limosus
Ralstonia species
Haemophilus influenzae
Anaerobic bacteria (e.g. Prevotella sp., Bacteroides sp.,
Porphyromonas sp.)
Unlikely pathogen in CF
Stenotrophomonas maltophilia
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proteins to accommodate neutrophil transmigration [18].
The neutrophils while important in pathogen clearance,
undergo necrosis resulting in DNA release and
increased mucous viscosity, compounding the problem
of bacterial attachment. Another aspect of host defense
that is compromised in CF is macrophage  clearance of
pathogens. Recent evidence suggests that dysfunctional
CFTR in macrophages impairs bacteriocidal activity
against P. aeruginosa [19], but the specific role of CFTR
in macrophage killing remains undefined and contro-
versial. Many humoral components of immunity are
also ineffective in CF. Host defense peptides (HDPs)
are impaired due to the dehydrated mucous of the ASL
[1] and secretion of proteases in the CF lung further
compromises immune function. In particular, neutro-
phil elastase predominates and in addition to destroying
a range of anti-microbial proteins, degrades mucin [20]
and increases IL-8 secretion from epithelial cells [21].
This is significant because Bcc strains have enhanced
growth in the presence of IL-8 [22]. Dysregulation of
matrix metalloproteases (MMPs) in CF is another con-
tributor to CF lung disease and to bacterial colonisa-
tion. Adult CF patients show elevated levels of serum
MMP-1, MMP-8 and MMP-9 [23] and elevated MMP-9
in lower airway secretions [24]. Recently, we have
shown that while P. aeruginosa predominantly activates
MMP-2 in CF lung epithelial cells, B. cenocepacia in-
fection activated MMP-9 only, the latter resulting in a
delay in wound healing [25].
The host response in CF may be further affected by
gender. Female CF patients have poorer survival rates
than males. This has been attributed to estradiol reducing
the ASL volume of CF epithelia in vitro [26]. More
recently, treatment of P. aeruginosa-infected male
CFTR-knockout mice with 17b-estradiol resulted in an
increased secretion of pro-inflammatory-chemokines and
chemoattractant-chemokines compared to controls [27],
indicating that estrogens also have a direct effect on host
response. Many of the elevated cytokines were Th17-
mediators, which is significant in the context of the IL-23/
IL-17 dependence of neutrophil recruitment during P.
aeruginosa infection [28]. A 99% reduction in lactoferrin
mRNA and a higher lung bacterial burden, was also
observed in estrogen treated mice, relative to the control
group. Many aspects of the host response in CF are
therefore either impaired or dysregulated by chronic in-
fection and may be further modulated by hormones, with
potential significant consequences for the host.
Adaptation of bacterial pathogens to the CF
lung
Adaptations of CF pathogens facilitate colonisation in the
challenging host environment or the avoidance of host
immune detection and antibiotic attack. The clinical
impacts of many of these adaptations have been compre-
hensively reviewed by Hauser et al. [29]. Hypermutable
bacteria have an increased mutation rate of up to 1000-
fold. It has been well established that hypermutable
populations have been identified among CF pathogens,
including P. aeruginosa, H. influenzae and S. aureus, con-
tributing to their adaptability. This hypermutability of
CF pathogens is illustrated by a study demonstrating that
68 genetic alterations accumulated in P. aeruginosa iso-
lates from a chronically colonised CF patient over 8 years.
Many of these genetic alterations were also identified in
isolates from 29 other patients and were virulence genes
associated with the initiation of infection which were
selected against over time [30]. In a follow-up study, it
was apparent that anti-microbial resistance genes were
not over-represented among these hypermutated genes
suggesting a more general adaptation to the CF lung [31]
rather than to treatment regimens.
Phenotypic changes in P. aeruginosa during chronic
infection have been well documented. P. aeruginosa
isolated from patients with acute respiratory infection
are generally non-encapsulated, expressing a variety of
invasive virulence factors including flagella, type IV
pili, multiple secreted toxins and degradative enzymes
whereas P. aeruginosa isolates from chronically infected
patients typically lack invasive virulence factors and
convert to a mucoid phenotype during the establish-
ment of chronic infection. This phenotype is associated
with biofilm formation and resistance to phagocytosis.
Phenotypic changes in Bcc isolates during the course of
infection have also been described. In contrast to P.
aeruginosa, Bcc changes from a mucoid to a non-mucoid
phenotype during chronic colonisation and patients
which were infected exclusively with non-mucoid
Bcc had a more rapid decline in lung function than
those infected with mucoid bacteria [32]. Bcc mucoid
isolates also lost expression of virulence factors and
acquired a mutation in a quorum sensing (QS) gene
during chronic infection [33]. Furthermore, proteomic
analysis of clonal B. cenocepacia variants obtained during
long-term colonisation showed an increase in peptido-
glycan synthesis enzymes, iron uptake and chaperone
proteins in later isolates, further demonstrating the
adaptation of these organisms to the lung environment
[34].
S. aureus can establish infection in the CF lung by
adaptation using some of the strategies already discussed
for P. aeruginosa. It also forms robust biofilms and ica
expression is upregulated under hypoxic conditions,
further promoting biofilm formation in oxygen deprived
regions of the CF lung [35]. Small colony variants (SCV)
of S. aureus frequently cultured from the CF lung are
associated with higher rates of intracellular invasion [11].
There is also some evidence of hypermutable strains of S.
aureus in CF and similar to other successful CF patho-
gens, this organism also downregulates certain virulence
genes during chronic infection [36].
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All three of these CF pathogens modulate virulence
mechanisms during chronic infection, however the phe-
notypic changes that occur in these different organisms
over time are very varied and the significance of many of
these changes to the establishment of infection and to CF
lung disease is not fully understood.
Specific strategies to evade host response
Bacterial invasion of the epithelium may provide an
effective escape from the host response or antibiotic
therapy for some pathogens or maybe a host clearance
mechanism for others. Whatever the consequences of
bacterial uptake by epithelial cells, phagocytosis by the
immune cells directs the pathogen towards death by
either oxidative or non-oxidative means. In addition to
biofilm formation providing resistance to phagocytosis,
additional strategies are also used to overcome this host
response mechanism. P. aeruginosa can evade phagocy-
tosis by becoming non-motile [37]. Similarly, Staphylo-
coccus aureus forms polysaccharide encased cells under
oxygen limited conditions which confer resistance to
neutrophil killing [35]. Bcc strains are inherently resistant
to non-oxidative killing [38] and some Bcc strains can also
survive within macrophages by inhibiting phagosome–
lysosome fusion [39].
Many CF pathogens disrupt epithelial integrity by open-
ing the intracellular tight junctions, providing a possible
mechanism for infiltration of pathogens within lung tissue
and enabling access to receptors on the basolateral side of
the epithelium, potentially provoking further inflam-
mation. P. aeruginosa disrupts tight junctions relatively
slowly as measured by a gradual drop in transepithelial
electrical resistance and a concomitant decrease in the
expression of the tight junction protein, ZO-1 within 24 h
of infection [40]. By contrast, Bcc induces a more rapid
disruption in epithelial integrity with a reduction in ZO-1
within 4 h, suggesting that different mechanisms are
involved [41]. Certain Pandoraea pulmonicola isolates also
impair epithelial integrity within 4 h [4]. This difference
in the rate of epithelial barrier disruption may be signifi-
cant, since P. aeruginosa is not associated with septicemia
in CF patients, while Bcc-associated septicemia has been
widely reported.
Quorum sensing facilitates adaptation
Virulence of many pathogens is regulated by QS signaling
systems that are dependent on bacterial cell density.
Three QS systems operate in P. aeruginosa, las, rhl and
pqs which function in an interconnecting network, facil-
itating co-operation and cheating within P. aeruginosa
populations [42]. The virulence gene regulation of P.
aeruginosa is well studied and many virulence determi-
nants including motility and biofilm formation are QS
dependent as reviewed recently [43,44]. QS signaling
molecules also appear to have direct effects on host cells
via calcium signaling. It was recently shown that the
P. aeruginosa QS autoinducer molecule 3O-C12-HSL
dramatically disrupted lung epithelial integrity by
calcium-mediated alterations in tight junction protein
interactions [45]. QS also regulates many S. aureus viru-
lence genes as recently reviewed by Goerke and Wolz
(2010) [36]. In particular, the agr QS system has a negative
effect on S. aureus biofilm formation. During chronic
infection, QS mutations occur to varying extents in CF
pathogens. Although the diversity of QS deficient variants
of P. aeruginosa in the CF lung is high [46], and agr S.
aureus mutants are regularly isolated from CF lungs, QS
mutations were infrequently observed among clinical B.
cenocepacia isolates and those with QS mutations were
growth impaired relative to wild type [47]. These findings
suggests significant species differences in these regulat-
ory networks and again highlight that CF pathogens
implement different strategies to establish chronic infec-
tions.
Variable oxygen concentrations and low iron
Successful CF pathogens have adapted to survive in a
range of oxygen concentrations found in the CF lung. P.
aeruginosa grows maximally in a microaerobic environ-
ment and the presence of cyanide in CF sputum suggests
that regions of the CF lung facilitate the optimal growth
of P. aeruginosa under microaerophilic conditions [48]. P.
aeruginosa also adapts well to anaerobic niches in the lung
and P. aeruginosa CF isolates have increased transcription
of genes involved in both denitrification and fermentation
[49]. Bcc are also cyanogenic under biofilm and colonial
growth conditions [50]. Therefore, both of these patho-
genic species are capable of adapting to varied oxygen
availability which is fundamental to their survival and
proliferation in the CF lung.
In addition to oxygen, a key element for the survival of all
pathogens is iron. Pathogens overcome the iron depleted
environment in the lung, primarily by the production of
iron chelating siderophores, transported across the mem-
brane via specific receptors. Pyoverdine and pyochelin are
both produced by P. aeruginosa and levels of intracellular
iron in this species affect surface motility and biofilm
maturation. Production of siderophores by Bcc are
reviewed by Thomas (2007) [51]. Ornibactin is the most
significant siderophore produced by Bcc organisms and
has been implicated in their survival in a mouse model
[52]. In addition to the production of siderophores, some
CF pathogens can also use exogenous siderophores from
other species to acquire iron. P. aeruginosa’s iron-regulated
genes, respond to ornibactin from Burkholderia [53] and
over thirty different siderophore receptors have been
identified in P. aeruginosa strains as reviewed in [54]
facilitating the uptake of exogenous siderophores. To
counteract the iron scavenging mechanisms of invading
pathogens, the host secretes the siderophore binding
protein, siderocalin and phagocytes also acquire iron from
some bacterial siderophores. However, recent evidence of
74 Host-microbe interactions: bacteria
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increased expression of siderophore receptors by clonal B.
cenocepacia variants obtained during long-term colonisa-
tion [34] suggests an adaptive strategy by this pathogen to
overcome any host response to limit iron availability.
Adaptation to high concentrations of
antibiotics
Most CF pathogens are notoriously difficult to eliminate
with antibiotic therapy. Many CF isolates are more resist-
ant to antibiotics in the biofilm mode of growth [55,56].
Slow bacterial growth and reduced metabolic activity, in
addition to the physical barrier of the biofilm matrix all
contribute to this phenomenon. In addition to biofilm
formation, CF pathogens also undergo mutations of anti-
biotic target sites and proactively eliminate antibiotics by
enzymatic cleavage as in the case of b-lactam antibiotics
or by efflux mechanisms. Four multidrug efflux systems
are reported to play a role in the antibiotic resistance of P.
aeruginosa CF isolates with the MexXY-OprM system
playing the predominant role in aminoglycoside resist-
ance [57]. A recent study of the genetic pathways
involved in Bcc antibiotic resistance revealed that they
were also multifactorial and include beta lactamases,
novel efflux pumps, a phenylacetic acid degradative path-
way and phosphohydrolases [58]. Both P. aeruginosa and
Bcc therefore have an array of strategies which allow them
to tolerate high doses of antibiotics delivered to the lung.
The challenge in developing novel antimicrobial thera-
pies is to identify new targets which can by-pass or
overcome the array of bacterial resistance mechanisms.
Future directions
The key to understanding the complex interactions be-
tween host and pathogen is having relevant models for
their study. However, the development of representative
CF animal models has been challenging. Mouse models
have been limited as CF-mice generally exhibit a normal
lung physiology without mucous plug obstruction. More
recently developed CF-pig and CF-ferret models demon-
strated mucous gland secretions that resemble those of
human CF [59,60]. The lungs of newborn CF-piglets
showed evidence of airway obstruction and reduced era-
dication of instilled bacteria [61]. CF-ferrets showed a
higher abundance of bacteria in two-day old animals, but
this difference was not maintained in animals that died
after one week [59]. Analysis of these models continues
and it may be several years before they become effective
tools for host-pathogen interaction studies. Until then,
many microbial pathogenesis studies in CF will continue
to be performed with immortalised lung epithelial cells,
ideally in the more physiologically relevant polarised
format. A more relevant approach, albeit of scarce supply,
is using primary cultures from explanted lungs of CF
patients at transplant. The difficulties with this model
were recently highlighted by Brodlie et al., where many
cultures were overgrown by bacteria which colonised the
patients [62]. Those successful bacteria-free cultures
formed a polarised epithelium, expressing phenotypes
of well differentiated CF primary cells, yet this differ-
entiated phenotype did not extend beyond two passages
[62], limiting their use for detailed investigation of host–
microbial interactions.
Finally, further research is required into the host–
microbial interactions of the less studied CF pathogens,
for example, A. xyloxidans, Pandoraea and NTM, and
more importantly, inter-bacterial interactions in the poly-
microbial community that persists in the CF lung.
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